In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CardioDx: Bringing Molecular Diagnostics Into the Cardiovascular Arena

Executive Summary

Buoyed by their success with Genomic Health, a trio of West Coast VCs have expanded their portfolios of molecular diagnostic companies, with many following similar themes. CardioDx has developed a test to distinguish between patients who should move on to cardiac imaging and those they are comfortable managing otherwise. Such a rule-out test is a challenging proposition. But if adopted, and more broadly, as molecular diagnostics move into new and broad markets like cardiology and metabolic disease, pharma could use this opportunity to its advantage in many settings, including co-marketing arrangements.
Advertisement

Related Content

GE’s Health Care Venture Adventure
Is Diagnostics the New Biotech...and Will Pharma Embrace It?
Medical Device and In Vitro Diagnostics/Research Deals Statistics Quarterly, Q1 2011
Personalized Medicine In 2010: Welcome To The Establishment
The Shake Up At Endo Pharma
Radiation Safety Concerns Could Drive New Legislation, Quality Standards
Another Call for Better Risk Stratification in Cardiac Imaging
Another Call for Better Risk Stratification in Cardiac Imaging
How to Earn the Economic Payback Diagnostics Companies Deserve
Profiles of COURAGE: Another Speed Bump for Stents or Flawed Trial?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003457

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel